Compare HubSpot Inc (HUBS) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HubSpot Inc vs Summit Therapeutics Inc — how do they compare? HubSpot Inc trades at $228.3 (market cap $11.56B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, HubSpot Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold HubSpot Inc for 78 Days and Summit Therapeutics Inc for 16 Days on average.
| HUBS | SMMT | |
|---|---|---|
Market Cap | $11.56B | $13.71B |
Volume | 1,891,287 | 6,173,057 |
Sector | Technology | Health |
52-Week High | $494.58 | $26.38 |
52-Week Low | $170.39 | $12.43 |
Typical Hold Time | 78 Days | 16 Days |
Enterprise Value | $10.46B | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $231.84, up 5.23% over the past day, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust revenue growth, improving profitability, and positive cash flow trends, supported by an AI-focused strategy unveiled at its recent Analyst Day. Analyst consensus is bullish with a $243.65 price target, though high valuation multiples and competitive pressures remain considerations.
The outlook for HUBS is positive, driven by AI integration, margin expansion targets, and consistent revenue growth. Key risks include elevated valuation metrics, potential AI-driven demand headwinds, and insider selling activity. The stock presents a growth opportunity but requires monitoring of execution against ambitious targets and competitive dynamics in the CRM software space.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
